
Mabylon AG
Schlieren, Switzerland · mabylon.com
On your own
Free. Their own form.
Through Midgard
Midgard sends your request to the lab and keeps the order's messages, papers and payments in one place. Free to ask. 1% platform fee if you keep the order on Midgard.
Mabylon AG is a clinical-stage biotechnology company in Schlieren, Switzerland. It develops engineered antibody therapeutics for allergy, inflammation, and neurology, using human-derived antibody repertoires and single-cell screening. The company also pursues clinical development of its own pipeline and collaborates on external therapeutic targets.
They take quote requests by email.
What they offer
Antibody discovery and engineering
Discovers and engineers novel antibody therapeutics from human-derived immune repertoires.
Single-cell antibody screening
Uses single-cell screening to pair native heavy and light chains and identify antibody hits.
High-throughput antibody expression
Rapidly clones and expresses B-cell screening hits as monoclonal antibodies.
Functional antibody evaluation
Selects the most functional and therapeutically relevant antibodies in downstream assays and preclinical models.
Multispecific antibody reformatting
Reformats promising antibodies into multispecific therapies when needed.
What they work on
- Modalities
- Small molecule, Antibody, Bispecific
- Species and models
- patients' immune repertoires, selected animal species
- Assays and studies
- single-cell screening, functional assays, antibody engineering, B-cell screening
- Therapeutic areas
- allergy, inflammation, immunology, neurology, neurodegenerative diseases
- Turnaround
- Within two to three weeks, B cell screening hits are cloned and expressed as monoclonal antibodies.
- Sites
- Schlieren, Switzerland · Zrich, Switzerland
- Address
- Wagistrasse 14 8952 Schlieren Switzerland
- Founded
- 2009
Similar labs. CDI Labs, Aurora Biolabs, Avenue Biosciences, Beantown Biotech
Found in a contract services directory. Listing built from mabylon.com. Work here? Claim this listing.